FDA drafts guidance on using next-generation sequencing to assess gene therapy safety - RAPS
FDA has drafted guidance on using next-generation sequencing (NGS) to assess gene therapy safety, which may affect quality control and release testing for gene therapy products. This could impact manufacturers of gene therapies and related biologics.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers and contract manufacturers involved in gene therapy development and production. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period typically 60-90 days from publication in Federal Register (not yet published).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued draft guidance recommending NGS for safety testing of gene therapies, potentially changing accepted methods for viral vector characterization and integration site analysis.
Who it affects
Branded drug makers and contract manufacturers involved in gene therapy development and production.
What you must do
Review the draft guidance and assess whether current testing methods align with FDA's recommendations. Prepare to comment on the draft if desired.
Deadline
Comment period typically 60-90 days from publication in Federal Register (not yet published).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness